Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Signaling Lymphocytic Activation Molecule Family Member 7 (SLAMF7)
- Target
- SLAMF7
- Molecular classification
- Type I transmembrane protein, Receptor, Signaling lymphocytic activation molecule family
01
Overview
Signaling lymphocytic activation molecule family member 7 (SLAMF7), also known as CD319, CS1, or CRACC, is a transmembrane protein and a member of the SLAM family of receptors. It plays key roles in immune cell signaling and has become an important therapeutic target, especially in multiple myeloma. It enhances cytotoxicity of NK cells by promoting degranulation upon engagement with its ligand (homophilic binding), modulates B cell activity and adaptive immunity, and regulates macrophage function. It is highly expressed on malignant plasma cells in multiple myeloma.
- Other names
- CD319CS1CRACC
02
Mechanism of action
Antibody-dependent cellular cytotoxicity (ADCC), direct ligation between NK/myeloma cells, Inhibition of TRAF6 autoubiquitination
03
Biological functions
Immune responseNK cell activationT cell regulationB cell modulationMacrophage regulationCytokine secretionCell adhesionSignal transduction
04
Disease associations
Multiple myelomaAutoimmune diseasesInflammationCancer
05
Safety considerations
Potential for immune-related adverse eventsOn-target, off-tumor toxicity
06
Interacting drugs
Elotuzumab
07
Biomarkers
SLAMF7 expression level in plasma cells
Beyond the preview
Go deeper on Signaling Lymphocytic Activation Molecule Family Member 7 (SLAMF7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Signaling Lymphocytic Activation Molecule Family Member 7 (SLAMF7).